Chemkart Live Share Price Today, Share Analysis and Chart

About the company - Business Profile

Chemkart India Ltd. (Chemkart) is a nutraceutical solutions platform based in Mumbai, India. The company has evolved from a domestic trading entity into an integrated enterprise encompassing sourcing, manufacturing, and formulation of ingredients. Chemkart operates within the high-growth nutraceutical market, which is projected to reach USD 76 billion by 2033. The company serves as a critical intermediary and producer of nutraceutical and amino acid-based ingredients, focusing on both domestic and export markets.

Key Points

• Key Facts:
  • Incorporation Year: 2020 (CIN: L51220MH2020PLC338631).
  • Headquarters: Santacruz (East), Mumbai, Maharashtra.
  • Stock Listing: Listed on the NSE (SME platform) following an IPO in FY 2024-25.
  • Leadership: Mr. Ankit Shailesh Mehta (Chairman and Managing Director).
  • Promoters: Shailesh Vinodrai Mehta and Ankit Shailesh Mehta.
• Operations and Resources:
  • Integrated Model: The company integrates sourcing, in-house manufacturing, and contract development (CDMO) through its subsidiaries.
  • Manufacturing Assets: Currently developing a major facility under its subsidiary, Easy Raw Materials Pvt. Ltd. (ERMPL), located at the JNPA SEZ, Navi Mumbai. As of November 2025, foundation and piling works (21 piles) are completed, with civil works scheduled for completion in Q4 FY 2025-26 and validation in early FY 2026-27.
  • R&D and Branding: Subsidiary Vinstar Biotech Pvt. Ltd. (VBPL) focuses on research, development, and branded formulation products.
• Market and Significance:
  • Industries Served: Nutraceuticals, dietary supplements, and food ingredients.
  • Strategic Importance: The company is transitioning to an export-driven integrated player to capture the global demand for amino acids and specialized health ingredients.
  • Certifications: Holds ISO 9001:2015, ISO 22000:2018, HALAL, KOSHER, and FSSAI licenses.
• Financial Performance (Standalone):
  • Total Assets: Rs 13,705.30 lakh as of September 30, 2025, compared to Rs 8,643.91 lakh as of March 31, 2025.
  • Liquidity: Following its IPO, the company reported cash and cash equivalents of Rs 4,374.58 lakh (Sep 2025), a significant increase from Rs 283.13 lakh in March 2025.
  • Working Capital: Inventory stood at Rs 2,280.94 lakh and trade receivables at Rs 5,619.17 lakh as of September 2025.
  • Cash Flow: Financing activities (primarily IPO proceeds) contributed Rs 4,028.35 lakh during the half-year ended September 2025.
• Business Model and Innovation:
  • The business model is built on supply chain integration, moving from raw ingredient trading to high-margin finished formulations and contract manufacturing.
  • Key Products: Amino acid-based ingredients, specialty nutraceuticals, and finished health formulations.
  • Infrastructure: The JNPA SEZ facility is designed to specifically handle export operations and in-house formulation to reduce reliance on third-party manufacturers.
• Current Strategic Initiatives:
  • Post-IPO Transformation: Utilizing funds for the construction of the ERMPL SEZ facility and expanding the branded product portfolio of VBPL.
  • Long-term Goal: Aims to become a fully integrated nutraceutical enterprise by FY 2026-27.
  • Global Expansion: Increasing focus on export growth and establishing international partnerships to leverage the integrated manufacturing capabilities.

References

1. Result Nov 2025
2. Investor Presentation Nov 2025